| Dr Jeffrey Parker Henderson, MD | |
|
1 Barnes Jewish Hospital Plz, Div Im Hospitalist, Saint Louis, MO 63110-1003 | |
| (314) 362-1700 | |
| (314) 362-9878 |
| Full Name | Dr Jeffrey Parker Henderson |
|---|---|
| Gender | Male |
| Speciality | Infectious Disease |
| Experience | 22 Years |
| Location | 1 Barnes Jewish Hospital Plz, Saint Louis, Missouri |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1558378851 | NPI | - | NPPES |
| 201476207 | Medicaid | MO |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RI0200X | Internal Medicine - Infectious Disease | 2006020971 (Missouri) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Barnes Jewish Hospital | Saint louis, MO | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Washington University | 9830008770 | 2506 |
News Archive
Tibotec Pharmaceuticals today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for TMC278 (rilpivirine), an investigational non-nucleoside reverse transcriptase inhibitor (NNRTI), being studied for once-daily use with other antiretroviral agents in treatment-naive HIV-1-infected adults. If approved, TMC278 will be the third anti-HIV compound to be introduced by Tibotec Pharmaceuticals.
Production capacity for biopharmaceutical manufacturing will expand an average of 46% over the next five years for mammalian production systems, according to a new report by BioPlan Associates.
On Friday, Michael J. Klag, MD, MPH, dean of the Johns Hopkins Bloomberg School of Public Health, wrote to U.S. Secretary of Agriculture Tom Vilsack to express his disappointment with USDA's recent retraction of Meatless Monday endorsement.
The court said the state didn't present evidence that the regulations furthered women's health. Elsewhere, a bill to stop employers from denying birth control coverage in their plans is considered in New York.
› Verified 7 days ago
| Entity Name | Washington University |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1992746903 PECOS PAC ID: 9830008770 Enrollment ID: O20031119000372 |
News Archive
Tibotec Pharmaceuticals today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for TMC278 (rilpivirine), an investigational non-nucleoside reverse transcriptase inhibitor (NNRTI), being studied for once-daily use with other antiretroviral agents in treatment-naive HIV-1-infected adults. If approved, TMC278 will be the third anti-HIV compound to be introduced by Tibotec Pharmaceuticals.
Production capacity for biopharmaceutical manufacturing will expand an average of 46% over the next five years for mammalian production systems, according to a new report by BioPlan Associates.
On Friday, Michael J. Klag, MD, MPH, dean of the Johns Hopkins Bloomberg School of Public Health, wrote to U.S. Secretary of Agriculture Tom Vilsack to express his disappointment with USDA's recent retraction of Meatless Monday endorsement.
The court said the state didn't present evidence that the regulations furthered women's health. Elsewhere, a bill to stop employers from denying birth control coverage in their plans is considered in New York.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Jeffrey Parker Henderson, MD Po Box 60352, Saint Louis, MO 63160-0352 Ph: (314) 362-1700 | Dr Jeffrey Parker Henderson, MD 1 Barnes Jewish Hospital Plz, Div Im Hospitalist, Saint Louis, MO 63110-1003 Ph: (314) 362-1700 |
News Archive
Tibotec Pharmaceuticals today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for TMC278 (rilpivirine), an investigational non-nucleoside reverse transcriptase inhibitor (NNRTI), being studied for once-daily use with other antiretroviral agents in treatment-naive HIV-1-infected adults. If approved, TMC278 will be the third anti-HIV compound to be introduced by Tibotec Pharmaceuticals.
Production capacity for biopharmaceutical manufacturing will expand an average of 46% over the next five years for mammalian production systems, according to a new report by BioPlan Associates.
On Friday, Michael J. Klag, MD, MPH, dean of the Johns Hopkins Bloomberg School of Public Health, wrote to U.S. Secretary of Agriculture Tom Vilsack to express his disappointment with USDA's recent retraction of Meatless Monday endorsement.
The court said the state didn't present evidence that the regulations furthered women's health. Elsewhere, a bill to stop employers from denying birth control coverage in their plans is considered in New York.
› Verified 7 days ago
Dr. Isik Turker, MD Infectious Disease Medicare: Medicare Enrolled Practice Location: 4921 Parkview Pl, Div Im Cardiology, Ste 8b, Saint Louis, MO 63110 Phone: 314-362-1291 Fax: 314-362-4278 | |
Conor Mccartney, M.D. Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 915 N Grand Blvd, Saint Louis, MO 63106 Phone: 314-652-4100 | |
Dr. Faris Adam Bakeer, MD Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 1 Barnes Jewish Hospital Plz, Div Im Hospitalist, Saint Louis, MO 63110 Phone: 314-362-1700 Fax: 314-362-9878 | |
Rehan Rais, M.D. M.B.,B.S. Infectious Disease Medicare: Medicare Enrolled Practice Location: 660 S Euclid Ave, Saint Louis, MO 63110 Phone: 314-362-5000 | |
Nathan Farkas, M.D. Infectious Disease Medicare: Not Enrolled in Medicare Practice Location: 1 Barnes Jew Hosp Plz, Saint Louis, MO 63110 Phone: 314-362-1930 | |
Dr. Nicole Foley, M.D. Infectious Disease Medicare: Medicare Enrolled Practice Location: 1 Barnes Jewish Hospital Plz, Saint Louis, MO 63110 Phone: 314-362-5000 | |
Soumojit Ghosh, Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 3660 Vista Ave, Saint Louis, MO 63110 Phone: 314-977-6100 Fax: 314-977-6164 |